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ABSTRACT
Introduction: Hypoglycaemia and hypergly-
caemia are common adverse events associated
with antidiabetic medications. They are also a
common cause of hospital admissions for peo-
ple with diabetes. The objective of the study was
to explore the trends in hospital admissions due
to hypoglycaemia and hyperglycaemia and in
the prescriptions of antidiabetic medications in
England and Wales.
Methods: We conducted an observational
study during the period 1999–2016. Hospital
admission data for patients from all age groups
were extracted from the Hospital Episode
Statistics database in England and the Patient
Episode Database for Wales. Data on prescrip-
tions of antidiabetic medications were extracted
from the Prescription Cost Analysis database
from 2004 to 2016.
Results: Between 1999 and 2016, the hospital
admission rate increased by 173.0% [from 17.2
(95% CI 16.9–17.6) to 47.1 (95% CI 46.5–47.6) per
100,000 persons] for hypoglycaemia and by
147.0% [from 22.8 (95% CI 22.4–23.2) to 56.3
(95% CI 55.7–56.9) per 100,000 persons] for
hyperglycaemia. The prescription rate for all
antidiabetic medications increased between 2004
and 2016 by 116.0% [from 373.0 (95% CI
373.0–373.0) to 806.0 (95% CI 806.0–806.0) pre-
scriptions per 1000 persons]. There was a parallel
increase in the rate of antidiabetic medication
prescriptions during the same study period, with
correlation coefficients of 0.94 for hypoglycaemia
and 0.98 for hyperglycaemia, respectively.
Conclusions: There have been parallel increases
in the rate of admissions due to dysglycaemia
and the rate of antidiabetic prescriptions in
England and Wales. Further analytical studies
are required to investigate whether increased
admission for dysglycaemia is associated with
increased use of antidiabetic medications.
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In the United Kingdom, there are around
4 million people living with diabetes mellitus,
corresponding to an estimated prevalence rate
of about 6.2% in 2015 [1]. During the same year,
diabetes mellitus accounted for around 23,000
deaths in people aged between 20 and 79 years
old [1]. Diabetes mellitus is a chronic condition
in which glycaemic control should be managed
in order to prevent the development of com-
plications such as microvascular and
macrovascular diseases [2]. Antidiabetic ther-
apy, in addition to diet and lifestyle modifica-
tions, is an essential component of the
management of people with diabetes mellitus
with uncontrolled HbA1C levels [3, 4].
Current treatment guidelines recommend the
initiation of intensive diabetes therapy in uncon-
trolled HbA1C patients to achieve better control
over their HbA1C levels, since the use of a single
antidiabetic agent does not always achieve the
targeted glycaemic control [5]. One of the main
drawbacks of intensive antidiabetic therapy is the
incidence of adverse drug events such as hypogly-
caemic events [6]. On the other hand, inappropri-
ate use of antidiabetic therapy is the main leading
cause of raised blood glucose levels and the occur-
rence of hyperglycaemic events [7, 8].
Hospitalisation increased by 11.7% and
declined by 38.6% due to hypoglycaemia and
hyperglycaemia, respectively, among US Medi-
care beneficiaries aged 65 years and older
between 1999 and 2011 [9]. In England, a pre-
vious study showed that hypoglycaemic
admissions increased by 14.0% between 2005
and 2014 [10]. However, no study has investi-
gated hospital admissions due to hypergly-
caemia in patients aged below 65 years old.
The objective of this ecological study was to
explore national trends in hospital admissions
due to dysglycaemia among patients from all
age groups in England and Wales from 1999 to
2016. Additionally, we examined antidiabetic
medication prescriptions for the available
period of 2004–2016 to investigate a potential
correlation between the trend in admissions
due to dysglycaemia and the trend in antidia-
betic medication prescriptions.
METHODS
Study Sources and the Population
This was a secular trend study using publicly
available national data taken from the Hospital
Episode Statistics (HES) database in England [11]
and the Patient Episode Database for Wales
(PEDW) for the period between April 1999 and
March 2016 [12]. The HES and PEDW databases
contain hospital admission data for hypogly-
caemia and hyperglycaemia in patients from all
age groups that were subdivided into four cat-
egories; below 15 years, 15–59 years, 60–
74 years, and 75 years and above. Hospital
admissions were identified using the diagnostic
codes E16.0, E16.1, E16.2, and T38.3 for hypo-
glycaemia admissions and E10.1, E11.1, E12.1,
E13.1, E14.1, and R73.9 for hyperglycaemia
admissions from the 10th version of the Inter-
national Statistical Classification of Diseases
(ICD) system. Admission codes for hypogly-
caemia and hyperglycaemia were consistent
with those used in previous studies [9, 10, 13].
Hyperglycaemia admission codes were selected
and included based on the clinical fact that
ketoacidosis, if presented in patients with dia-
betes mellitus, is considered a sign of hyper-
glycaemia, where the body is unable to produce
enough insulin in response to raised blood
glucose levels [14]. In addition, the diagnostic
code (R73.9) was selected based on its descrip-
tion, which stands for unspecified
hyperglycaemia.
HES and PEDW are the main healthcare
databases in England and Wales. They record all
hospital admissions, outpatients and Accident
and Emergency (A&E) activities performed at all
National Health Service (NHS) trusts and any
independent sector funded by NHS trusts. Data
for hospital admissions in England and Wales
are available from the years 1999/2000 onwards.
Available data include patient demographics,
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clinical diagnoses, procedures, and durations of
stay. HES and PEDW data are checked regularly
to ensure their validity and accuracy [11, 15].
Mid-year population data for the period
between 1999 and 2016 were collected from the
Office for National Statistics (ONS) to calculate
the admission rate on a yearly basis [16].
Antidiabetic medication prescription data in
England and Wales were extracted from the
Prescription Cost Analysis (PCA) database for
the available period of April 2004–March 2016
[17, 18]. The PCA database provides informa-
tion about all items that are prescribed by gen-
eral practitioners and other healthcare
professionals, such as hospital physicians,
pharmacists and nurses, and dispensed in the
community, whether by dispensing physicians,
pharmacy contractors or appliance contractors
in England and Wales [19–21]. The British
National Formulary (BNF) therapeutic classifi-
cation system is used to report the data to the
PCA database. Prescription data became avail-
able in England from 2004 [17] and in Wales
from 2000 [18]. Only prescriptions dispensed in
the community in England and Wales and
submitted to NHS Prescription Services are
reported in the PCA database [19]. The accuracy
of the prescriptions recorded in the PCA data-
base was estimated by NHS Prescription Services
to reach 98.5% for patients in England and
99.2% for patients in Wales [19, 22].
Compliance with Ethics Guidelines
This study was based on publicly available data
and did not involve any new studies of human
or animal subjects performed by any of the
authors.
Statistical Analysis
Hospital admission rates with their 95% confi-
dence intervals (CIs) were calculated using the
number of hypoglycaemia/hyperglycaemia
admissions for each age group divided by the
mid-year population of the same age group of
the same year. Antidiabetic prescription rates
were calculated using the number of
antidiabetic prescriptions divided by the total
mid-year population during the same year.
The chi-squared test was used to assess the
difference between the admission rates in 1999
and 2016 and the difference between the
antidiabetic medication prescription rates in
2004 and 2016. The trend in hospital admis-
sions for hypoglycaemia and hyperglycaemia
was assessed using a Poisson model. The corre-
lation between hospital admissions for hypo-
glycaemia/hyperglycaemia and antidiabetic
prescriptions was assessed using the Pearson
correlation coefficient. All analyses were per-
formed using SAS version 9.3 (SAS Institute,
Cary, NC, USA).
RESULTS
The annual number of hospital admissions for
hypoglycaemia rose from 8985 in 1999 to
27,485 in 2016, representing an increase of
173.0% [from 17.2 (95% CI 16.9–17.6) per
100,000 persons in 1999 to 47.1 (95% CI
46.5–47.6) in 2016, trend test, p\0.01]. The
rate of hospital admissions due to hypergly-
caemia over the same period increased by
147.0% [from 22.8 (95% CI 22.4–23.2) to 56.3
(95% CI 55.7–56.9) per 100,000 persons]
(Fig. 1a), with 11,904 admissions in 1999 and
32,867 admissions in 2016. There were no sig-
nificant differences in hypoglycaemia and
hyperglycaemia admission rates between men
and women (p[0.05).
The increases in the rates of admissions due
to hypoglycaemia and hyperglycaemia were
synchronised with an increase in the rate of
antidiabetic medication prescriptions from all
therapeutic classifications; the correlation
coefficients were 0.94 and 0.98, respectively
(Fig. 2).
The hospital admission rate due to hypogly-
caemia and the rates of insulin and sulfonylurea
prescriptions all increased in parallel, with a
correlation coefficient of 0.96 obtained for both
insulin and sulfonylurea. The correlation coef-
ficients for hypoglycaemia and biguanides or
other antidiabetics were 0.94 and 0.85, respec-
tively. The increase in the rate of admissions
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due to hyperglycaemia was synchronised with
the increase in the rates of antidiabetic medi-
cation prescriptions from all therapeutic classi-
fications. The correlation coefficients were 0.99,
0.94, 0.98 and 0.95 for insulin, sulfonylurea,
biguanides and other antidiabetics, respectively.
In 2015/2016, unspecified hypoglycaemia
was the main cause of hypoglycaemic admis-
sions, contributing 78.0% of the total number
of admissions due to hypoglycaemia (Table 1).
Ketoacidosis in patients with insulin-dependent
diabetes mellitus was the main reason for hos-
pital admission due to hyperglycaemia, con-
tributing 73.4%. These proportions were similar
to the proportions of the whole period of the
study at which unspecified hypoglycaemia and
ketoacidosis among patients with insulin-de-
pendent diabetes mellitus were the key reasons
for dysglycaemia admissions, contributing to
80.0% and 72.7% of those admissions, respec-
tively, for the period between 1999 and 2016.
Antidiabetic Medication Prescriptions
The total number of antidiabetic prescriptions
dispensed annually in England and Wales
increased from 19.8 million in 2004 to
47.0 million prescriptions in 2016. Prescrip-
tion rates for all antidiabetic medications
between 2004 and 2016 increased by 116.0%
[from 373.0 (95% CI 373.0–373.0) to 806.0
(95% CI 806.0–806.0) prescriptions per 1000
persons].
Antidiabetic prescription rates of sulfony-
lurea, insulin, biguanide and other antidiabetic
medications increased by 41.6% [from 109.0
(95% CI 109.0–109.0) to 154.0 (95% CI
154.0–154.0) prescriptions per 1000 persons],
51.5% [from 84.8 (95% CI 84.7–84.9) to 129.0
(95% CI 128.0–129.0) prescriptions per 1000
persons], 152.0% [from 150.0 (95% CI
150.0–150.0) to 378.0 (95% CI 377.0–378.0)
prescriptions per 1000 persons] and 399.0%
[from 29.1 (95% CI 29.1–29.2) to 145.0 (95% CI




Hospital admissions due to hypoglycaemia were

















Total insulin Sulphonylureas Biguanides Other Andiabec Drugs
Fig. 2 Prescription rates of antidiabetic medications in England and Wales
bFig. 1a–c Hospital admission rates due to dysglycaemia in
England and Wales between 1999 and 2016. a Hypogly-
caemia and hyperglycaemia admission rates in England and
Wales for the total population. b Rates of hospital
admissions due to hypoglycaemia across different age
groups. c Rates of hospital admissions due to hypergly-
caemia across different age groups
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rates for patients aged 75 years and above were
higher than those aged 60–74 years, followed by
patients aged 15–59 years and below 15 years
(Fig. 1b). Between 1999 and 2016, hospital
admission rates increased for all age groups. The
highest increase in admission rate was in the
age group 75 years and above, which increased
by 267.0% [from 63.9 (95% CI 61.4–66.4) to
234.0 (95% CI 230.0–239.0) per 100,000 per-
sons], followed by the age group 15–59 years,
which increased by 126.0% [from 10.4 (95% CI
10.0–10.7) to 23.3 (95% CI 22.8–23.9) per
100,000 persons], and then the age group below
15 years, which increased by 124.0% [from 12.4
(95% CI 11.7–13.1) to 27.7 (95% CI 26.7–28.7)
per 100,000 persons], and the age group 60–
74 years, which increased by 112.0% [from 29.0
(95% CI 27.7–30.2) to 61.3 (95% CI 59.7–63.0)
per 100,000 persons].
The rates of hypoglycaemia admission in
2015/2016 for patients aged 75 years and
above were 3-fold, 10-fold and 8-fold higher
than the rates among patients aged 60–




Hospital admissions due to hyperglycaemia
were found to be higher in those aged 15–
59 years and 75 years and above, followed by
patients aged 60–74 years and those below
15 years (Fig. 1c). Between 1999 and 2016, hos-
pital admission rates increased markedly—by
198.0% [from 25.7 (95% CI 24.1–27.3) to 76.5
(95% CI 74.1–79.0) per 100,000 persons]—in
those aged 75 years and above, followed by
170.0% [from 25.2 (95% CI 24.7–25.8) to 68.2
(95% CI 67.3–69.1) per 100,000 persons] in the
15–59 years group, then by 119.0% [from 18.7
(95% CI 17.7–19.7) to 40.9 (95% CI 39.6–42.2)
per 100,000 persons] in the 60–74 years group,
and by 24.6% [from 17.0 (95% CI 16.2–17.8) to
21.2 (95% CI 20.3–22.1) per 100,000 persons] in
the age group below 15 years.
Compared with patients aged 60–74 years,
15–59 years and below 15 years, the rate of
hyperglycaemia admission in patients aged
75 years and above in 2015/2016 was approxi-
mately double, the same, and quadruple,
respectively.




E16.0 Drug-induced hypoglycaemia without coma 6.0
E16.1 Other hypoglycaemia 4.6
E16.2 Hypoglycaemia, unspeciﬁed 78.0
T38.3 Poisoning: insulin and oral hypoglycaemic (antidiabetic) drugs 11.4
Hyperglycaemia ICD codes
E10.1 Insulin-dependent diabetes mellitus—with ketoacidosis 73.4
E11.1 Non-insulin-dependent diabetes mellitus—with ketoacidosis 19.4
E12.1 Malnutrition-related diabetes mellitus—with ketoacidosis 0.0
E13.1 Other speciﬁed diabetes mellitus—with ketoacidosis 0.4
E14.1 Unspeciﬁed diabetes mellitus—with ketoacidosis 1.1
R73.9 Hyperglycaemia, unspeciﬁed 5.7
ICD International Statistical Classiﬁcation of Diseases system
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DISCUSSION
Our study found a significant increase in the
rate of hospital admissions due to hypogly-
caemia and hyperglycaemia in England and
Wales, with an average increase of 10.2% and
9.2%, respectively, per year during the past
17 years. This increase was accompanied by a
rise in the rate of antidiabetic medication pre-
scriptions from all therapeutic classifications
during the past 13 years.
The average annual increase in the preva-
lence rate of diabetes mellitus in England in the
past 10 years is estimated to be 7.7% [23] and
4.0% in Wales [24]. Prevalence data in England
and Wales are restricted only for patients aged
17 years and above, and are estimated based on
the percentage of diabetes mellitus patients
registered in the total practice list [23, 24]. The
increase in antidiabetic prescriptions may
reflect an increase in the prevalence of diabetes
itself or an intensification of treatment in peo-
ple with diabetes. Based on the available
prevalence data, we assume that the average
yearly increase in the rate of dysglycaemia
admissions and the rate of antidiabetic medi-
cation prescriptions was higher than the aver-
age increase in the prevalence of diabetes
mellitus. Based on this, we hypothesise that
intensive antidiabetic therapy using multiple
antidiabetic medications has played a role in
increasing the rate of dysglycaemia admissions
in the past few years (i.e. hypo may be associ-
ated with aggressive treatment and hyper could
be the result of uncontrolled diabetes due to
nonadherence). This hypothesis was tested by a
study conducted in the USA, which found that
patients who were exposed to intensive therapy
were at higher risk of hypoglycaemia admission
[25]. Furthermore, it was found that the higher
the number of medications being used, the
more likely it is that the patient will be non-
adherent, which diminishes the benefit of
therapy and increases the risk of harm [26].
We are unable to make a direct comparison
with previous studies as they used different ICD
codes. The rate of dysglycaemia admissions in
our study was higher than in previous studies
[9, 10, 27]. There are several possible
explanations for this. First, the study design
itself: as this study is an ecological study mon-
itoring trends in dysglycaemia admission at the
population level without access to patient-level
data, we cannot be certain that all of these
admissions are for patients with diabetes melli-
tus. Second, different ICD codes were used in
the identification of hypoglycaemia admission.
This study included ICD code T38.3 [poisoning:
insulin and oral hypoglycaemic (antidiabetic)
drugs], which contributed 11.1% of the hypo-
glycaemia admissions. As investigated in a pre-
vious study on hyperglycaemia admissions, we
used the ICD code E10.1 [9], in addition to four
other ICD codes (E11.1, E12.1, E13.1 and E14.1)
that are based on the presence of ketoacidosis,
as well as the ICD code R73.9, which is used for
unspecified hyperglycaemia. These additional
five ICD codes contributed around 27.2% of the
hyperglycaemia admissions. Third, different age
groups were investigated. Fourth, different
study periods were examined. Finally, different




The increase in admissions due to hypogly-
caemia in England and Wales found in our
study is higher than what has been reported
previously in the USA (11.7%) [9] and in Eng-
land (14.0%) [10]. Those studies reported that
admissions increased by 1.0% and 1.4% per
year, respectively. However, a study in Canada
reported that the hypoglycaemia admission rate
decreased by 50.0% over a period of 12 years
between 2002 and 2013, at an average of 4.2%
per year [27].
Our study confirmed that there is a differ-
ence between the hypoglycaemia admission
rates for patients from different age groups.
Patients aged 60 years and older are at higher
risk of hypoglycaemia-related admission than
younger patients, which is consistent with pre-
vious studies [9, 10, 28]. Hypoglycaemia in
older people could be influenced by several
factors, such as susceptibility to hypoglycaemia
and other adverse events, cognitive
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dysfunction, disease comorbidities, and the use
of multiple medications [29]. In addition, more
aggressive antidiabetic treatment of patients
could potentially explain the increasing rate of
hypoglycaemia over the last 17 years.
The factors that contribute to hypoglycaemia
differ between patients aged 15 years and below
and older patients. Children have a higher pos-
sibility of developing 2–5 (or even more) mild
hypoglycaemic events per week, and are also at
high risk of severe events [30]. Furthermore, a
previous study has reported that the presence of
other comorbidities (for example, gastroenteri-
tis) in children is associated with hypoglycaemia
events [31]. While we do not have data on the
prescribing of insulin in children, it is reasonable
to assume that the increased rate of hypogly-
caemia admissions may be attributable to the use
of insulin for the treatment of type I diabetes
mellitus (T1DM) in children.
Hyperglycaemia-Related Hospital
Admissions
The increase in admissions due to hypergly-
caemia in England and Wales is higher than and
opposite to what was observed in the USA,
where there was a decrease of 38.6% between
1999 and 2011, representing an average 3.2%
decline per year [9].
In line with the USA-based study [9], our
study found that patients aged 75 years and
above were at particularly high risk of admis-
sion due to hyperglycaemia. We also found that
young patients aged 15–59 years were at higher
risk of hospital admission due to hypergly-
caemia than other age groups. No previous
study has reported hyperglycaemia in this
young age group of patients.
In 2015/2016, our study found that 73.4% of
hyperglycaemia admissions were coded ‘‘in-
sulin-dependent diabetes mellitus—with
ketoacidosis’’, highlighting that hyperglycaemia
admission is prevalent among uncontrolled
HbA1C patients treated with insulin. This could
explain the reason for the higher rate of
hyperglycaemia admissions in the group aged
15–59 years, since T1DM is common among
young adults aged 40 years and below [32].
Furthermore, for patients aged 75 years and
above, the raised rate of hyperglycaemia
admissions could be due to uncontrolled dia-
betes and the use of insulin therapy to achieve a
better control over the disease.
Several factors could potentially stimulate
uncontrolled hyperglycaemia, such as a seden-
tary lifestyle, an unhealthy diet, inappropriate
use of oral antidiabetic medications and insulins,
and inappropriate administration of insulins
[33]. Adherence to antidiabetic therapy and
infections are also considered important factors
that are linked with the incidence of hypergly-
caemic episodes [6]. Medication adherence
among people with diabetes is influenced by age,
complexity of treatment and use of polyphar-
macy [7]. Poor adherence to antidiabetic therapy
consisting of multiple antidiabetic medications
could explain raised blood glucose levels and
therefore poor disease control. Additionally,
patient behaviour towards and perceptions of
their medications have been linked to adherence
and can contribute to increased admissions
related to hyperglycaemia among patients aged
15–59 years. It has been observed that younger
patients may feel that they have other priorities
and are able to manage their disease without
adhering to physician directions regarding their
medication regimen [34]. Furthermore, antidia-
betic medication adverse events and (especially)
hypoglycaemia are important issues related to
nonadherence to therapy [35], and consequently
increase the incidence of hyperglycaemic events.
Based on the evidence, we suggest that elderly
patients aged 75 years and above may experience
hyperglycaemic events due to fear of hypogly-
caemic events.
Trends in Dysglycaemia Admissions
and Antidiabetic Medication Prescriptions
We found a simultaneous increase in the rate of
admissions due to dysglycaemia and the pre-
scription rates of all antidiabetic medications
from all therapeutic classifications with corre-
lation coefficients ranging from 0.94 to 0.99,
reflecting a strong positive linear relationship.
Our research has generated an important
safety signal on the potential inappropriate use
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of antidiabetic medications among patients
with diabetes mellitus. This signal urgently
requires investigation. Future analytical studies
should be conducted to investigate whether
intensifying antidiabetic treatment using mul-
tiple antidiabetic medications or by increasing
the dose is associated with hypoglycaemia, and
whether uncontrolled blood glucose is associ-
ated with intensive antidiabetic treatment.
Earlier studies have shown that insulin therapy
and insulin secretagogues are high-risk medi-
cations that are most frequently associated with
hypoglycaemic events [6, 36]. Based on current
evidence, healthcare professionals should be
aware of the risk of dysglycaemia that is asso-
ciated with the use of antidiabetic medications.
Furthermore, educating children with diabetes
and their parent/caregiver on the appropriate
insulin management and administration is a
vital part of diabetes management [37].
Strengths and Limitations
The study was a population study at the
national level. However, it was an ecological
study and therefore we were unable to access
data on patient level to confirm that these
hypoglycaemia and hyperglycaemia admissions
were of patients with diabetes mellitus. Fur-
thermore, we were unable to identify other risk
factors such as the presence of comorbidities,
the presence of polypharmacy or other factors
associated with hypoglycaemia and hypergly-
caemia without patient level data. Other limi-
tations include a lack of information on gender
at age group level, rural/urban residence and
ethnicity for dysglycaemia admission or antidi-
abetic medication prescription data.
CONCLUSIONS
This study suggests that there are parallel
increases in the rate of hospital admissions due
to dysglycaemia and the rate of antidiabetic
prescriptions in England and Wales over the
past 13 years. Further studies should be con-
ducted at the patient level to investigate the
association between the use of multiple
antidiabetic medications and the risk of hypo-
glycaemic and hyperglycaemic events.
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